Navigation Links
Nobel laureate to keynote international pharmaceutical conference at URI
Date:6/7/2012

KINGSTON, R.I. June 7, 2012 The University of Rhode Island will hold a global pharmaceutical sciences conference featuring Nobel Prize winner Thomas Steitz from Sept. 28 through 30 at its Kingston Campus.

Steitz, the Sterling Professor of Molecular Biophysics and Biochemistry and professor of chemistry at Yale University, will speak Sunday, Sept. 30 at 9 a.m. Steitz, who was awarded the Nobel Prize for Chemistry in 2009 with two other scientists, is also an investigator at Yale's Howard Hughes Medical Institute.

Registration is required and full details about the conference can be found at http://www.uri.edu/pharmacy/frontiers/2012/index.html. The program is one of many to be held in conjunction with the September grand opening of the new URI College of Pharmacy building, a $75 million facility supported primarily by Rhode Islanders.

Conference co-organizer Navindra Seeram, URI assistant professor of biomedical and pharmaceutical sciences and director of the Bioactive Botanical Research Laboratory, said he believes this will be the largest conference of its kind in the history of the University.

"The Northeast Corridor of the United States is the center of pharmaceutical science research and industry and so this is an ideal location for a program of this type," Seeram said. "The participation of some of the world's leading biomedical scientists, including Yale's Professor Steitz, is an indication of the high regard they have for research going on at URI's College of Pharmacy and, indeed, the ongoing scientific work of many of our colleges. We have attracted renowned scientists from every portion of the globe, including researchers in India and Pakistan who have partnerships with us."

Conference co-organizer Keykavous Parang, URI professor of medicinal chemistry and pharmacology, said the conference will offer one of the most dive
'/>"/>

Contact: Dave Lavallee
dlavallee@advance.uri.edu
401-874-5862
University of Rhode Island
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
2. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
3. Kessler Foundation researchers present at first International Congress on Cognition in MS
4. International conference to explore health of descendants of transatlantic slave trade
5. International breast health global summit will focus on supportive care and quality of life
6. MSU invention could help pharmaceutical industry save money
7. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
8. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
9. Blending conference translates substance abuse research into practice
10. NJ stroke researchers report advances in spatial neglect research at AAN Conference
11. Elsevier organizes label-free technologies conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... ... president of the National Dental Association (NDA) at 6 p.m. on December 5 at the ... ... will be installed as the 86th president of the National Dental Association (NDA) at 6 ...
... ... N.Y. Times #1 best-seller KNOCKOUT , ... Cornwall, NY (PRWEB) December 2, 2009 -- In her new book KNOCKOUT, Interviews ... Place, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments--treatments that ...
... Award-winning author ... from Patients on Becoming a Doctor, that traces his wild path through the third year ... ... point or another, either find themselves dressed in a tiny hospital gown or staring at ...
... , , ... syndicated radio show, Dr. Rafael Pelayo, Associate Professor at the Stanford ... Ecotones Duet Sleep Sound Machine as part of a healthy sleep ... minimal use of drugs. , "Background noise is a problem for ...
... 2 A randomized, controlled study comparing standard conservative therapy ... painful herniated disc revealed that while both treatments help patients ... free up to two years later. Results of the study, ... annual meeting of the Radiological Society of North America (RSNA). ...
... , SEATTLE, Dec. 2 Cell Therapeutics, Inc. ... M.D. of St. George,s Hospital, University of London, the lead ... data on the pixantrone phase III trial in relapsed/refractory aggressive ... American Society of Hematology on Saturday, December 5, 2009 in ...
Cached Medicine News:Health News:Meharry Medical College Officer Will Head the National Dental Association 2Health News:Meharry Medical College Officer Will Head the National Dental Association 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Beneath the Short White Coat: A Medical Student Reveals All 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 2Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 4
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
... participate in controversial debate over effects of ... Simvastatin vs. Ezetimibe/Simvastatin, ... medical professionals, will air on XM Satellite Radio Channel,157 ... a candid medical,discussion on the much talked-about ENHANCE (Effect ...
... the Addition of L-MTP-PE to, Chemotherapy ... Osteosarcoma Patients, IRVINE, Calif., Feb. 4 ... the Journal of Clinical Oncology (JCO) has,published findings ... entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to,Chemotherapy ...
Cached Medicine Technology:ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 3IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 4IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 5IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 6IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 7
... leads are small profile endocardial permanent pacing ... a lead body size of only 4.8 ... 7 F, the Physique lead is the ... Available in both straight and pre-formed J ...
Used with Temporary Myocardial Heartwires....
Used with permanent pacing leads....
Suture sleeve for permanent pacing leads....
Medicine Products: